FDA Approves Expanded Age Indication for RSV Vaccine - Medscape
FDA Approves Expanded Age Indication for RSV Vaccine Medscape
RSV (Respiratory Syncytial Virus) News
Respiratory Viruses - Cabinet for Health and Family Services - Cabinet for Health and Family Services (CHFS) (.gov)
Respiratory Viruses - Cabinet for Health and Family Services Cabinet for Health and Family Services (CHFS) (.gov)
Respiratory syncytial virus (RSV) - World Health Organization (WHO)
Respiratory syncytial virus (RSV) World Health Organization (WHO)
Respiratory Illnesses Data Channel - Centers for Disease Control and Prevention | CDC (.gov)
Respiratory Illnesses Data Channel Centers for Disease Control and Prevention | CDC (.gov)
FDA Approves GSK's RSV Vaccine for Adults Aged 18-49 at Increased Risk - Pharmacy Times
FDA Approves GSK's RSV Vaccine for Adults Aged 18-49 at Increased Risk Pharmacy Times
GSK's RSV shot cleared in US for all adults - pharmaphorum
GSK's RSV shot cleared in US for all adults pharmaphorum
Flu deaths in Georgia hit highest level in five years - Healthbeat
Flu deaths in Georgia hit highest level in five years Healthbeat
RSV Vaccine Eligibility Expands - Conexiant
RSV Vaccine Eligibility Expands Conexiant
Weekly respiratory virus update, week 10, March 2026 - European Centre for Disease Prevention and Control
Weekly respiratory virus update, week 10, March 2026 European Centre for Disease Prevention and Control
Arexvy FDA expanded age 18 49 RSV vaccine - Infectious Disease Special Edition
Arexvy FDA expanded age 18 49 RSV vaccine Infectious Disease Special Edition
When to seek care for cold, flu and RSV - Mayo Clinic Health System
When to seek care for cold, flu and RSV Mayo Clinic Health System
Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent - BioSpace
Naobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge Agent BioSpace
Current and Emerging Strategies for the Prevention of Respiratory Syncytial Virus (RSV) Infections: A Comprehensive Review of Vaccines and Antibody Therapies - Cureus
Current and Emerging Strategies for the Prevention of Respiratory Syncytial Virus (RSV) Infections: A Comprehensive Review of Vaccines and Antibody Therapies Cureus
The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation - The Lancet
The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation The Lancet
New ECDC Panel to Develop Adult RSV Vaccination Guidance - Medscape
New ECDC Panel to Develop Adult RSV Vaccination Guidance Medscape
The soluble G protein of respiratory syncytial virus promotes viral dissemination via TLR2-mediated NLRP3 priming and pyroptosis - Nature
The soluble G protein of respiratory syncytial virus promotes viral dissemination via TLR2-mediated NLRP3 priming and pyroptosis Nature
RSV Symptoms, Causes & Treatment - Cleveland Clinic
RSV Symptoms, Causes & Treatment Cleveland Clinic
WHO outlines recommendations to protect infants against RSV – respiratory syncytial virus - World Health Organization (WHO)
WHO outlines recommendations to protect infants against RSV – respiratory syncytial virus World Health Organization (WHO)
Respiratory Syncytial Virus (RSV) Vaccine Safety - Centers for Disease Control and Prevention | CDC (.gov)
Respiratory Syncytial Virus (RSV) Vaccine Safety Centers for Disease Control and Prevention | CDC (.gov)
WHO Health Emergencies EPI-WIN webinar: respiratory syncytial virus (RSV) genomic surveillance – how & why - World Health Organization (WHO)
WHO Health Emergencies EPI-WIN webinar: respiratory syncytial virus (RSV) genomic surveillance – how & why World Health Organization (WHO)
A little-known respiratory virus, human metapneumovirus, surging in Northern California - University of California - Davis Health
A little-known respiratory virus, human metapneumovirus, surging in Northern California University of California - Davis Health
The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants - Cureus
The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants Cureus
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk - Business Wire
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk Business Wire
Correlates of risk of respiratory syncytial virus disease: a prospective cohort study - Nature
Correlates of risk of respiratory syncytial virus disease: a prospective cohort study Nature
Economic Burden of Respiratory Syncytial Virus Infection in Colombia: A Nationwide Cost-of-Illness Study - Journal of Health Economics and Outcomes Research
Economic Burden of Respiratory Syncytial Virus Infection in Colombia: A Nationwide Cost-of-Illness Study Journal of Health Economics and Outcomes Research
Protect Yourself from RSV: Who Needs the Vaccine and Why It Matters - The National Council on Aging (NCOA)
Protect Yourself from RSV: Who Needs the Vaccine and Why It Matters The National Council on Aging (NCOA)
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids - CIDRAP
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids CIDRAP
RSV vaccine protects older adults, and drug protects babies, but less so over time, studies suggest - CIDRAP
RSV vaccine protects older adults, and drug protects babies, but less so over time, studies suggest CIDRAP
CDC reports 11 more pediatric flu deaths as several key flu indicators fall slightly - CIDRAP
CDC reports 11 more pediatric flu deaths as several key flu indicators fall slightly CIDRAP
Respiratory syncytial virus (RSV) resources - American Medical Association
Respiratory syncytial virus (RSV) resources American Medical Association
Can Adults Get RSV? What to Know About Symptoms, Treatment, and Prevention - University of Rochester Medical Center
Can Adults Get RSV? What to Know About Symptoms, Treatment, and Prevention University of Rochester Medical Center
Respiratory syncytial virus (RSV) tied to heart problems - Harvard Health
Respiratory syncytial virus (RSV) tied to heart problems Harvard Health
Studies: RSV prevention strategies—especially nirsevimab—may cut infant hospitalizations - CIDRAP
Studies: RSV prevention strategies—especially nirsevimab—may cut infant hospitalizations CIDRAP
Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers - NEJM Evidence
Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers NEJM Evidence
In 2023-24, RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates - CIDRAP
In 2023-24, RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates CIDRAP
RSV Vaccine Excels in Preventing Severe ARI in Seniors - Medscape
RSV Vaccine Excels in Preventing Severe ARI in Seniors Medscape
Whole-genome nanopore sequencing and automatic downstream analysis of respiratory syncytial virus using RSVTyper - Nature
Whole-genome nanopore sequencing and automatic downstream analysis of respiratory syncytial virus using RSVTyper Nature
RSV around the World: The Good (and Bad) News - Scientific American
RSV around the World: The Good (and Bad) News Scientific American
Quick Take: Respiratory Syncytial Virus - Medscape
Quick Take: Respiratory Syncytial Virus Medscape
A living systematic review and meta analysis on the efficacy and safety of respiratory syncytial virus vaccines - European Centre for Disease Prevention and Control
A living systematic review and meta analysis on the efficacy and safety of respiratory syncytial virus vaccines European Centre for Disease Prevention and Control